Active Filter(s):
Details:
The primary objective of this collaboration is to identify and validate potential treatment responsive CMT1A biomarkers that could be further explored in future clinical studies, in particular the upcoming Phase III study of PXT3003, Pharnext’s lead drug candidate.
Lead Product(s): Baclofen,Naltrexone,Sorbitol API
Therapeutic Area: Genetic Disease Product Name: PXT3003
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Pharnext
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 03, 2020